NEW YORK (GenomeWeb) – Janney Capital Markets today announced it has upgraded shares of T2 Biosystems to a Buy rating on the results of its first quarter financial update.

Analyst Paul Knight upgraded shares from a previous rating of Neutral and reiterated his target share price of $25 for the company's stock.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.